Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 5,277 matching trials from the live ClinicalTrials.gov search.
Filters: Gainesville, Florida Clear all
Active, not recruiting Phase 2 Interventional

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

NCT05897424
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema
Interventions
SAR447537
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 5, 2026, 1:42 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

NCT03921541
View directory record Official record
Conditions
Arginase I Deficiency, Hyperargininemia
Interventions
Pegzilarginase, Placebo
Drug
Lead sponsor
Immedica Pharma AB
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
17
States / cities
Rogers, Arkansas • Orange, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 5, 2026, 1:42 PM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

NCT04808505
View directory record Official record
Conditions
Glycogen Storage Disease Type II Infantile Onset
Interventions
Cipaglucosidase alfa, Miglustat
Biological · Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
Up to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Gainesville, Florida • Atlanta, Georgia • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Nov 5, 2026, 1:42 PM EST
Completed Phase 1 Interventional Results available

A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

NCT04279613
View directory record Official record
Conditions
Type I Diabetes
Interventions
NNC0361-0041, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
16
States / cities
Orange, California • San Francisco, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Nov 5, 2026, 1:42 PM EST
Recruiting Phase 2 Interventional

Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial

NCT05758246
View directory record Official record
Conditions
Sepsis, Acute Infection, Organ Failure
Interventions
Fisetin-dose 1, Fisetin-dose 2, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Gainesville, Florida • Iowa City, Iowa • Burnsville, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 5, 2026, 1:42 PM EST
Recruiting Phase 1Phase 2 Interventional

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

NCT05101070
View directory record Official record
Conditions
Solid Tumors
Interventions
S-531011, Pembrolizumab, Bevacizumab
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 5, 2026, 1:42 PM EST
Completed Phase 3 Interventional Results available

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

NCT00036270
View directory record Official record
Conditions
Breast Neoplasms
Interventions
exemestane (Aromasin), tamoxifen + exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older · Female only
Enrollment
9,779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
179
States / cities
Bessemer, Alabama • Birmingham, Alabama • Flagstaff, Arizona + 139 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Nov 5, 2026, 1:42 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
IV Tulisokibart, IV Placebo, SC Tulisokibart, SC Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
76
States / cities
Dothan, Alabama • Fairhope, Alabama • Litchfield Park, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 5, 2026, 1:42 PM EST
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

NCT02520388
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Newport Beach, California • Bradenton, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Nov 5, 2026, 1:42 PM EST
Terminated Not applicable Interventional

Syncardia 50cc TAH-t as a Bridge to Transplant

NCT02459054
View directory record Official record
Conditions
Heart Failure, Right-Sided, Cardiac Failure, Heart Failure, Left-Sided
Interventions
SynCardia 50cc temporary Total Artificial Heart (TAH-t)
Device
Lead sponsor
SynCardia Systems. LLC
Industry
Eligibility
10 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
26
States / cities
Tucson, Arizona • Los Angeles, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Nov 5, 2026, 1:42 PM EST
Completed No phase listed Observational Results available

Evaluation of Pancreatic Pseudocyst Drainage With a Metal Stent

NCT01239056
View directory record Official record
Conditions
Pancreatic Pseudocysts
Interventions
Endoscopy
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Nov 5, 2026, 1:42 PM EST
Completed Not applicable Interventional

The Feasibility of the PAINReportIt Guided Relaxation Intervention-INPATIENT

NCT02729350
View directory record Official record
Conditions
Sickle Cell Disease, Stress, Pain
Interventions
Guided Relaxation video clip, Sickle Cell Disease Experience Discussion
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Nov 5, 2026, 1:42 PM EST
Completed Phase 3 Interventional

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

NCT00043927
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
topotecan/cisplatin, etoposide/cisplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
66
States / cities
Hoover, Alabama • Chula Vista, California • Fountain Valley, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Nov 5, 2026, 1:42 PM EST
Completed No phase listed Observational

A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects

NCT02704273
View directory record Official record
Conditions
X-linked Myotubular Myopathy
Interventions
Not listed
Lead sponsor
Astellas Gene Therapies
Industry
Eligibility
Up to 3 Years · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Gainesville, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Nov 5, 2026, 1:42 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers

The Effect of Low Furanocoumarin Grapefruit Hybrid Juice Consumption on Midazolam Pharmacokinetics

NCT02117869
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Low furanocoumarin hybrid grapefruit juice, Regular grapefruit juice, Water (control)
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Nov 5, 2026, 1:42 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Probiotics on Stress-associated Gastrointestinal Function in University Students

NCT03056846
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Probiotic Combination, Bifidobacterium bifidum, Bifidobacterium longum
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
634 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Nov 5, 2026, 1:42 PM EST
Completed No phase listed Observational

Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT01142427
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
17,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
214
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Nov 5, 2026, 1:42 PM EST
Active, not recruiting Not applicable Interventional

Hospital-Based Cluster Trial: Magnetically Controlled Growing Rods Using Distraction Intervals

NCT04058561
View directory record Official record
Conditions
Early-Onset Scoliosis Deformity of Spine
Interventions
MAGEC® Spinal Bracing And Distraction System
Device
Lead sponsor
Pediatric Spine Foundation
Other
Eligibility
5 Years to 9 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
17
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 5, 2026, 1:42 PM EST
Completed No phase listed Observational

LMA Cuff Pressure and LMA-induced Complications

NCT01385969
View directory record Official record
Conditions
Sore Throat, Dysphagia, Dysphonia
Interventions
Standard inflation of LMA cuff, Pressure check with syringe recoil, Pressure check by pressure transducer
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Nov 5, 2026, 1:42 PM EST
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

NCT02851797
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
givinostat, placebo
Drug
Lead sponsor
Italfarmaco
Industry
Eligibility
6 Years to 17 Years · Male only
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Davis, California • San Diego, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Nov 5, 2026, 1:42 PM EST
Completed No phase listed Observational

ACE Inhibitors Combined With Exercise for Seniors - Pilot Study

NCT01891513
View directory record Official record
Conditions
Hypertension, Aging
Interventions
Exercise, ACE inhibitor + exercise, Thiazide diuretic + exercise, Angiotensin receptor blocker + exercise
Behavioral · Drug
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Nov 5, 2026, 1:42 PM EST
Completed Phase 4 Interventional

Effect of Celecoxib on Markers of Vascular Inflammation

NCT00471341
View directory record Official record
Conditions
Hypertension and Coronary Artery Disease
Interventions
Celecoxib, placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
50 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Gainesville, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Nov 5, 2026, 1:42 PM EST
Completed Phase 3 Interventional Results available

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

NCT03473223
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Apolipoprotein A-I [human] (apoA-I), Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
18,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
202
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Nov 5, 2026, 1:42 PM EST
Completed Phase 2 Interventional Results available

ACP-01 in Patients With Critical Limb Ischemia

NCT02551679
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
ACP-01, Placebo
Biological
Lead sponsor
Hemostemix
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
16
States / cities
Sacramento, California • Aurora, Colorado • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Nov 5, 2026, 1:42 PM EST